We report the case of a patient with rare CD5+ hairy cell leukemia, which was unusual, as there was also a discrepancy between the bone marrow and peripheral blood immunophenotypes. We propose that some degree of maturation within the malignant clone and the predominance of more mature CD5– hairy cells in the peripheral blood can explain this observation. The patient was treated with a conventional course of cladribine (2′-chlorodeoxyadenosine) and achieved complete remission. We conclude that the unusual CD5+ immunophenotype of this patient did not affect prognosis or change the response to standard therapy.

Keywords:
Hairy cell leukemia, Immunophenotype
1.
Platanias LC, Golomb HM: Hairy cell leukemia. Baillières Clin Haematol 1993;6:887–898.
2.
Jansen J, den Ottolander GJ, Schuit HRE, Waayer JLM, Hijmans W: Hairy cell leukemia: Its place among the chronic B cell leukemias. Semin Oncol 1984;11:386–393.
3.
Jansen J, LeBrien TW, Kersey JH: The phenotype of the neoplastic cells of hairy cell leukemia studies with monoclonal antibodies. Blood 1982;58:609–614.
4.
Stroup R, Sheibani K: Antigenic phenotypes of hairy cell leukemia and monocytoid B-cell lymphoma. Hum Pathol 1992;23:172–177.
5.
Kristensen JS, Elegaard J, Hokland P: A two-color flow cytometry assay for detection of hairy cells using monoclonal antibodies. Blood 1987;70:1063–1068.
6.
Golomb HM, Ratain MJ, Mick R, Daly K: The treatment of hairy cell leukemia: An update. Leukemia 1992;6(suppl 2):24–27.
7.
Wormsley SB, Baird SM: Characteristics of CD11c+ CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 1990;76:123–130.
8.
Salter DM, Krajewski AS, Cunningham S: Activation and differentiation antigen expression in B-cell non-Hodgkin’s lymphoma. J Pathol 1988;154:209–222.
9.
Foon KA: Chronic lymphoid leukemias: Recent advances in biology and therapy. Stem Cells 195;13:1–21.
10.
Jansen J: Hairy cell leukemia; in Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ (eds): Hematology. Basic Principles and Practice. New York, Churchill Livingstone, 1991, pp 1001–1008.
11.
Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT: Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic findings. Blood 1987;69:1617–1621.
12.
Hanson CA, Gribbin TE, Schnitzer B, Schlegelmilch JA, Mitchell BS, Stoolman LM: CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood 1990;76:2360–2367.
13.
Foon KA, Todd RF III: Immunologic classification of leukemia and lymphoma. Blood 1986;68:1–31.
14.
Falini B, Pulford K, Erber WMN, Posnett DN, Pallesen G, Schwarting R, Annino L, Cafolla A, Canino S, Mori A, Minelli O, Cianti C, Voxes EE, Golomb HM, Delson G, Stein H, Martelli MD, Grignani FI, Mason DY: Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocytochemical study of 36 cases. Histopathology 1986;10:671–687.
15.
Hess CE: Hairy cell lekemia, malignant histiocytosis, and related disorders; in Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN (eds): Wintrobe’s Clinical Hematology, ed 9. Philadelphia, Lea & Febiger, 1993, pp 2170–2200.
16.
DiGiuseppe JA, Borowitz MJ: Clinical utility of flow cytometry in the chronic lymphoid leukemia. Semin Oncol 1998;25:6–10.
17.
Hermann F, Dorken B, Ludwig WD: A comparison of membrane marker phenotypes in hairy-cell leukemia and phorbol-ester induced B-CLL cells using monoclonal antibodies. Leuk Res 1985;5:529–536.
18.
Kipps TJ, Robbins BA: Hairy-cell leukemia; in Lichtman MA, Collier BS, Kipps TJ; in Beutler E (ed): Williams Hematology, ed 5. New York, McGraw-Hill, 1995, pp 1040–1047.
19.
Robbins BA, Ellison DJ, spinosa JC, Carey CA, Lukes RJ, Poppema S, Sven A, Piro LD: Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993;82:1277–1287.
20.
Heimann PS, Vardman JW, Stock W, Platanias LC, Golomb HM: CD5+, CD11c+. Hairy cell leukemia. Blood 1991;77:1617.
21.
De Totero D, Tazzari PL, Lauria F, Raspadori D, di Celle PF, Carbone A, Gobbi M, Foa R: Phenotypic analysis of hairy cell leukemia: ‘Variant’ cases express the interleukin-2 receptor β chain, but not the α chain (CD25). Blood 1993;82:528–536.
22.
Falini B, Schwarting R, Erber W, Posnett DN, Martelli MF, Grignani F, Zuccacia M, Gatter KC, Cernetti C, Stein H, Mason DY: The differential diagnosis of hairy cell leukemia with a panel of monoclonal antibodies. Am J Clin Pathol 1985;83:289–300.
23.
Gressler VH, Weinkauff RE, Franklin WA, Golomb HM: Is there a direct differentiation-inducing effect of human recombinant interferon on hairy cell leukemia in vitro? Cancer 1989;64:374–378.
24.
Juliusson G, Lenkei R, Liliemark J: Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83:3672–3681.
25.
Lauria F, Zinzani PL, Raspadori D, Foa R, Buzzi M, Gugliotta L, Bocchia M, Benfenati D, Tura S: Relationship between immunological response to α-IFN treatment in 35 patients with hairy cell leukemia. Eur J Haematol 1990;45:3–6.
26.
Lauria F, Raspadori D, Foa R, Zinzani PL, Buzzi M, Gugliotta L, Macchi S, Tura S: Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype. Cancer 1990;65:2233–2236.
27.
Fridrik MA, Wahl G, Herbinger W, Schutzenberger W, Castl G, Huber C, Kronke M, Hopfel I: Morphological and immunological changes of hairy cell leukemia during α-2-interferon therapy. Blut 1989;58:261–264.
28.
Hsu S, Yang K, Jaffe ES: Hairy cell leukemia: A B cell neoplasm with a unique antigenic phenotype. Am J Clin Pathol 1983;80:421–428.
29.
Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D: The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B cell disorders. Blood 1994;83:1558–1562.
30.
Hassan IB, Habgerg H, Sundstrom C: Immunophenotype of hairy-cell leukemia. Eur J Haematol 1990;45:172–176.
31.
Batata A, Shen B: Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia. Cancer 1992;70:2436–2443.
32.
Stass S, Mirro J: Unexpected heterogeneity in acute leukemia: Mixed lineages and lineage switch. Hum Pathol 1985;16:864–866.
33.
Graves MF: ‘Target’ cells, cellular phenotypes, and lineage fidelity in human leukaemia. J Cell Physiol 1982;113(suppl):113–125.
34.
Tien H-F, Wang C-W: CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 1998;31:93–98.
35.
Greaves MF, Chan LC, Furley AJW, Watt SM, Molgaard HV: Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 1986;67:1–11.
36.
Ludwig W-D, Bartran CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Tiechmann JV, Reihm H: Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. Blood. 1988;71:151.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.